Intranasal replicating adenovirus type 4-vectored SARS-CoV-2 vaccines induce durable and efficacious responses in preclinical testing.

Differences in weight loss between groups that were challenged with SARS-CoV-2 Omicron on day 56 did not achieve significance, likely because this variant is not as virulent as Delta in hamsters ( Figure 4 B). 45 Following SARS-CoV-2 Omicron challenge at day 174, Ad4-Anc and Ad4-Delta-immunized animals had significantly less weight loss compared to the Ad4-H5 control group ( p = 0.002 and 0.005, respectively) as did Ad26.CoV2.S ( p = 0.043, both comparisons), although these differences were modest.

also in 1,397 other papers